益生菌冻干粉联合铋剂四联疗法治疗幽门螺杆菌感染的临床效果

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (34 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To observe the eradication rate and safety of Probiotics Freeze-Dried Powder combined with bismuth-containing quadruple therapy in the treatment of Helicobacter pylori(Hp)infection.Methods A total of 98 Hppositive patients who were diagnosed and treated in the outpatient clinic of our hospital from November 2016 to May 2017 were selected as the study subjects.They were randomly divided into quadruple medication group (49 cases)and combined medication group (49 cases).The quadruple medication group was treated with Rabeprazole,Amoxicillin,Clarithromycin and Colloidal Bismuth Pectin,while the combined medication group was further given Probiotics Freeze-Dried Powder on the basis of the quadruple medication group.The Hp eradication rate and the incidence rate of adverse reactions after treatment were compared between the two groups.Results The Hp eradication rate in the combined medication group was higher than that in the quadruple medication group,and the difference was statistically significant(P＜0.05).The incidence rate of adverse reactions was lower than that in the quadruple medication group,and the difference was statistically significant(P＜0.05).Conclusion Probiotics Freeze-Dried Powder combined with bismuth-containing quadruple therapy has a high eradication rate of Hp and fewer adverse reactions,which is appropriate for clinical promotion.

Key words： Helicobacter pylori Probiotics Freeze-Dried Powder Bismuth-containing quadruple therapy Clinical effect

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	AN Min
	GAO Zhen-jun

Cite this article:

AN Min,GAO Zhen-jun. Clinical effect of Probiotics Freeze-Dried Powder combined with bismuth-containing quadruple therapy in the treatment of Helicobacter pylori infection[J]. 中国当代医药, 2018, 25(23): 155-157转161.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2018/V25/I23/155

[1]	Hatakeyama M，Brzozowski T.Pathogenesis of Helicobacter pylori infection[J].Helicobacter，2006，11（S1）：14-20.
[2]	张万岱，胡伏莲，萧树东，等.中国自然人群幽门螺杆菌感染的流行病学调查[J].现代消化及介入诊疗，2010，15（5）：265-270.
[3]	Eusebi LH，Zagari RM，Bzzoli F，et al.Epidemiology of Helicobactor pylori infection[J].Helicobactor，2014，19（S1）：1-5.
[4]	胡福成，成虹，张学智，等.多中心临床观察荆花胃康联合三联疗法治疗幽门螺杆菌相关性十二指肠球部溃疡和胃炎疗效及耐药分析[J].中华医学杂志，2012，92（10）：679-684.
[5]	Zhang W，Chen Q，Liang X，et al.Bismuth，amoxicillin and metronidazole or clarithromycin as first time Helicobactor pylori therapy[J].Gut，2015，64（11）：1715-1720.
[6]	Liang X，Xu X，Zheng Q，et al.Efficacy of bismuth-containing quadruple therapies for clarithromycin，metronidazole，and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study[J].Clin Gastroenterol Hepatol，2013，11（7）：802-807.
[7]	Liu WZ，Xie Y，Cheng H，et al，Forth Chinese National Consensus Report on the management of Helicobacter pylori infection[J].J Dig Dis，2013，14（5）：211-221.
[8]	Higuchi K，Maekawa T，Nakagawa K，et al.Efficacy and safety of Helicobacter pylori eradication therapy with omeprazole，amoxicillin and high-and-low-dose clarithromycin in Japanese patients：a randomized，double-blind，multicentre study[J].Clin Drug Investig，2006，26（7）：403-414.
[9]	Archimandritis A，Souyioultzis S，Katsorida M，et al.Clostridium difficile associated with a triple regimen，containing clarithromycin and metronidazole，to eradicate Helicobacter pylori[J].J Intern Med，1998，（243）：251-253.
[10]	杜奕奇.微生物制剂联合三联疗法治疗幽门螺杆菌感染[J].现代消化及介入治疗，2010，15（1）：43-46.
[11]	Sgouras D，Maragkoudakis P，Petraki K，et al.Invitroand in vivo inhibition of Helicobacter pylori by Lactobacillus casei strain Shirota[J].Appl Environ Microbiol，2004，70（1）：518-526.
[12]	Zhang L，Su P，Henriksson A，et al.Investigation of the immunomodulatory effects of Lactobacter pylori infection[J].Helicobacter，2008，13（3）：183-190.
[13]	Brzozowski T，Konturek PC，Sliwowski Z，et al.Interaction of nonsteroidal anti-inflammatory drugs （NSAID） with Helicobacter pylori in the stomach of humans and experimental animals[J].J Physiol Pharmacol，2006，57（S3）：67.
[14]	Borody TJ，Pong G，Wettstein AR，et al.Efficacy and safety of rifabutin-containing rescue therapy for resistant Helicobacter pylori infection [J].Aliment Pharmacol Ther，2006，23（4）：481-484.
[15]	Seven G，Cinar K，Yakut M，et al.Assessment of Helicobacter pylori eradication rate of triple combination therapy containing levofloxacin[J].Turk J Gastroenterol，2011，22（6）：582-586.